ArticleHealth services research2011
Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results.
Article in Health services research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications.JAMA network open · 2019Trial
- Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice.Blood advances · 2025Review
- When to adjust for multiplicity in cancer clinical trials.Journal of the National Cancer Institute. Monographs · 2025Article
- How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?Blood reviews · 2023Review
- Policies and Practices to Address Cancer's Long-Term Adverse Consequences.Journal of the National Cancer Institute · 2022Article
- Transplant indications, guidelines and recommendations: Caveat Emptor.Bone marrow transplantation · 2022Article
- Does a durian smell like a rose? The dangers of jargon.Bone marrow transplantation · 2020Article
- To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs.Neuro-oncology · 2019Article
- Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells.Stem cells (Dayton, Ohio) · 2019Review
- Translation of Clinical Research into Practice: An Impact Assessment of the Results from the Blood and Marrow Transplant Clinical Trials Network Protocol 0201 on Unrelated Graft Source Utilization.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Article
- Is there expert consensus on expert consensus?Bone marrow transplantation · 2018Article
- Standardizing haematopoietic cell transplants in China.Journal of hematology & oncology · 2018Article
- Peer review in hematopoietic cell transplantation: are we doing our fair share?Bone marrow transplantation · 2016Article
- From evidence to clinical practice in blood and marrow transplantation.Blood reviews · 2015Review
- Towards understanding the de-adoption of low-value clinical practices: a scoping review.BMC medicine · 2015Article
- The oligometastatic state - separating truth from wishful thinking.Nature reviews. Clinical oncology · 2014Review
- Trends in PCI volume after negative results from the COURAGE trial.Health services research · 2014Article
- Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013Article
- Development of a Universal Electric Medical Clamp for Rotational Intraperitoneal Aerosol Chemotherapy.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 2 countries.
Funding
Abstract
objectiveIn 1999, three randomized controlled trials concluded that high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HDC/HCT) is no better than conventional chemotherapy for women with breast cancer. This study documents the impact of the trials on use of HDC/HCT and describes how hospitals reacted to the trials. DATA SOURCE: We used patient-level data on 15,847 HDC/HCTs reported to the Center for International Blood and Marrow Transplant Research between 1994 and 2005. STUDY
designWe report trends in total HDC/HCT procedure volume, compare the time to hospitals' exit from the HDC/HCT market between research and nonresearch hospitals, and document trends in hospital-specific volumes in the 2 years before exit. PRINCIPAL
findingsHDC/HCT volume declined from 3,108 in 1998 to 1,363 the year after trial results were released. In 2002, only 76 procedures were performed. Teaching hospitals and the hospitals that participated in the trials were no slower to discontinue the procedure compared with nonteaching, nonparticipating hospitals. At the hospital level, volume declined steadily in the months before abandonment.
conclusionThe results suggest that comparative effectiveness research studies that report negative results can reduce spending, but specialists may be reluctant to relinquish cutting-edge technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.